Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06451614
Other study ID # U0755
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date October 1, 2024
Est. completion date December 31, 2026

Study information

Verified date June 2024
Source Boston Scientific Corporation
Contact Reshma Rao
Phone 952-930-6000
Email reshma.rao@bsci.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To evaluate the safety and effectiveness of the SpaceITâ„¢ Hydrogel System in patients undergoing External Beam Radiotherapy (EBRT) for the treatment of prostate cancer.


Description:

HYDROSPACE study is a prospective, randomized, multicenter study to evaluate the safety and effectiveness of SpaceIT in patients undergoing External Beam Radiotherapy (EBRT) for the treatment of prostate cancer. Subjects randomized to the investigational arm will receive SpaceIT Hydrogel System Subjects randomized to the control arm will receive a commercially marketed Boston Scientific perirectal hydrogel spacer, SpaceOAR System or SpaceOAR Vue Hydrogel


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 230
Est. completion date December 31, 2026
Est. primary completion date December 31, 2025
Accepts healthy volunteers No
Gender Male
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Age =18 years old 2. Subjects must have had pathologically confirmed (by routine hematoxylin and eosin [H&E] staining) invasive adenocarcinoma of the prostate and planning to undergo EBRT 3. Subjects must have ALL of the following: 1. Clinical stage T1-T2c (AJCC Ver. 9) tumor AND 2. Gleason Score 7 or less as determined from a biopsy taken within 12 months of the Baseline visit AND 3. Demonstrated blood prostate specific antigen (PSA) levels =20 ng/ml as measured within 6 months of the Baseline visit and prior to commencing androgen deprivation therapy (ADT) 4. Subject is able to provide written informed consent, approved by the appropriate Institutional Review Board/Ethics Committee/Research Ethics Board (IRB/EC/REB) of the respective clinical site Exclusion Criteria: 1. Prostate > 80 cc 2. Subjects who are planning to undergo brachytherapy or focal boost 3. Subjects who have magnetic resonance imaging (MRI) evidence of gross posterior extracapsular extension (ECE) of the prostate cancer 4. Subjects who have metastatic disease, other ongoing cancers which are being treated during the study or subjects for whom pelvic lymph node radiotherapy is planned 5. Subjects with any prior invasive solid tumor malignancy or hematologic malignancy (except non-melanomatous skin cancer) unless the subject has been disease free and treatment free for a minimum of 3 years 6. History of radical prostatectomy, other ablative anti-prostate cancer therapy (e.g., cryotherapy, high intensity focused ultrasound, irreversible electroporation) or previous pelvic irradiation (including prior prostate brachytherapy) at any time prior to screening 7. History of transurethral prostate surgery (e.g., TUNA, TUMT, TURP) if performed within 1 year prior to screening 8. History of prior pelvic surgery requiring low anterior or abdominoperineal resections or rectal surgery 9. History of or current perirectal disease that may interfere with interpretation of study outcomes, including anal or perianal diseases such as fistula 10. Bleeding hemorrhoids requiring medical intervention within the prior three months 11. Diagnosed active bleeding disorder or a clinically significant coagulopathy 12. Active inflammatory or infectious process involving the perineum, GI or urinary tract based on positive diagnosis or suspected diagnosis in the presence of fever >38° C, WBC > 12,000/uL 13. Inability to undergo pelvic MRI or presence of implants causing severe artifact (e.g. bilateral arthroplasty) that interferes with imaging interpretation for this study at Investigator discretion 14. If a subject was enrolled in another investigational drug or device trial that had not completed the primary endpoint or that clinically interfered with this study 15. Unable to comply with the study requirements or follow-up schedule 16. Any condition the Investigator believed would interfere with the intent of the study or would make participation not in the best interest of the patient 17. Known PEG (polyethylene glycol) sensitivity or allergy 18. Known iodine sensitivity or allergy

Study Design


Related Conditions & MeSH terms


Intervention

Device:
SpaceIT Hydrogel System
SpaceIT Hydrogel System is intended to temporarily position the anterior rectal wall away from the prostate during radiotherapy for prostate cancer and in creating this space it is the intent of SpaceIT Hydrogel System to reduce the radiation dose delivered to the anterior rectum. The SpaceIT Hydrogel System is composed of a radiopaque, biodegradable material designed to maintain space for approximately 12 weeks and be absorbed in about 6 months, sufficient time to support the intended use. SpaceIT has an iodinated PEG powder making it radiopaque.
Commercially available Boston Scientific Spacer
Boston Scientific's commercially available SpaceOAR Hydrogel System or SpaceOAR Vue Hydrogel System is intended to temporarily position the anterior rectal wall away from the prostate during radiotherapy for prostate cancer and in creating this space it is the intent of SpaceOAR Hydrogel System or SpaceOAR Vue Hydrogel System to reduce the radiation dose delivered to the anterior rectum. SpaceOAR and SpaceOAR Vue are both perirectal spacers. SpaceOAR Vue specifically has an iodinated PEG powder making it radiopaque. SpaceOAR does not contain iodinated PEG powder and is not radiopaque. The SpaceOAR Hydrogel System or SpaceOAR Vue Hydrogel System maintains space during prostate radiotherapy treatment and is completely absorbed by the patient's body over time.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Boston Scientific Corporation

Outcome

Type Measure Description Time frame Safety issue
Primary Primary Safety Endpoint - Acute Grade 3 or greater adverse events related to the hydrogel placement or hydrogel misplacement resulting in a delay or cancellation of radiotherapy Acute Grade 3 or greater adverse events related to the hydrogel placement or hydrogel misplacement resulting in a delay or cancellation of radiotherapy within 90 days of index procedure. 90 Days from hydrogel placement procedure
Primary Primary Effectiveness Endpoint - 25% reduction in the volume of the rectum receiving 90% of the prescribed radiation dose Clinically relevant dose reduction defined as a 25% reduction in the volume of the rectum receiving 90% of the prescribed radiation dose in subjects receiving hydrogel. 10 days post procedure
Secondary Additional Safety Endpoint - Adverse Device Effects (ADEs) requiring additional procedures and/or medications Adverse Device Effects (ADEs) requiring additional procedures and/or medications Up to 24 months
Secondary Additional Safety Endpoint - Incidence of acute Grade 2 or greater gastrointestinal (GI) and genitourinary (GU) adverse events (AEs) Incidence of acute Grade 2 or greater gastrointestinal (GI) and genitourinary (GU) adverse events (AEs) from index procedure up to 3 months Up to 90 days
Secondary Additional Safety Endpoint - Incidence of late Grade 2 or greater GI and GU adverse events (AEs) Incidence of late Grade 2 or greater GI and GU adverse events (AEs) from 3 months up to the end of study follow-up 91 days up to 24 Months
Secondary Additional Effectiveness Endpoint - Visualization of hydrogel Technical Success: visualization of hydrogel between the posterior prostatic capsule and the anterior rectal wall will be assessed as Yes/No using the MRI performed post hydrogel placement procedure 10 days post procedure
Secondary Additional Effectiveness Endpoint - Space Creation Space Creation: Distance between the posterior prostatic capsule and anterior rectal wall will be measured mid gland in millimeters using MRI performed post hydrogel placement procedure 10 days post procedure
Secondary Additional Effectiveness Endpoint - Absorption Absorption: Absence of hydrogel in the perirectal space assessed on MRI at 12 months post-hydrogel placement. 12 Month post hydrogel placement
Secondary Additional Effectiveness Endpoint - Change in radiation dose distributions to the organs at risk Dose Distribution: Change in radiation dose distributions to the organs at risk (OARs) quantified by computing rectal Dose-Volume Histograms (DVHs) for the dose plans created pre-and post-hydrogel placement. 10 days post procedure
Secondary Additional Effectiveness Endpoint - Mean and Maximum Rectal Radiation doses Mean and Maximum Rectal Radiation Doses (in Gy) 10 days post procedure
Secondary Additional Effectiveness Endpoint - Quality of Life Questionnaire: EQ-5D-5L Changes from Baseline in EQ-5D-5L
The EQ-5D-5L is a generic questionnaire that assesses a subject's self-reported health status in terms of five dimensions of health: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. Each dimension has five response levels: no problems, slight problems, moderate problems, severe problems, unable to/extreme problems. Subject's overall current health on a vertical visual analogue scale of "0-100" is recorded, where the endpoints are labelled 'The best health you can imagine' at "100" and 'The worst health you can imagine' at "0".
Baseline up to 24 months
Secondary Additional Effectiveness Endpoint - Ease of hydrogel administration Ease of hydrogel administration. Scored on a Likert scale from 1 to 5 where 1 is Very Difficult and 5 is Very Easy 10 days post procedure
Secondary Additional Effectiveness Endpoint - Space Maintenance Space Maintenance: Distance between the posterior prostatic capsule and anterior rectal wall will be measured 3 Months post hydrogel placement procedure
Secondary Additional Effectiveness Endpoint - Quality of Life Questionnaire: Expanded Prostate Cancer Index Composite (EPIC-26) Changes from Baseline in Expanded Prostate Cancer Index Composite (EPIC-26)
EPIC-26 is a questionnaire designed to measure health related quality of life (HRQOL) in people with prostate cancer. Response options for each EPIC item form a Likert scale, and multi-item scale scores are transformed linearly to a 0-100 scale, with higher scores representing better HRQOL.
Baseline up to 24 months
Secondary Additional Effectiveness Endpoint - Quality of Life Questionnaire, Work Productivity and Activity Impairment Questionnaire: General Health (WPAI:GH) Changes from Baseline in Work Productivity and Activity Impairment Questionnaire: General Health (WPAI:GH)
The Work Productivity and Activity Impairment Questionnaire: General Health (WPAI:GH) outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity.
Baseline up to 24 months
See also
  Status Clinical Trial Phase
Recruiting NCT05540392 - An Acupuncture Study for Prostate Cancer Survivors With Urinary Issues Phase 1/Phase 2
Recruiting NCT05613023 - A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT Phase 3
Recruiting NCT05156424 - A Comparison of Aerobic and Resistance Exercise to Counteract Treatment Side Effects in Men With Prostate Cancer Phase 1/Phase 2
Completed NCT03177759 - Living With Prostate Cancer (LPC)
Completed NCT01331083 - A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer Phase 2
Recruiting NCT05540782 - A Study of Cognitive Health in Survivors of Prostate Cancer
Active, not recruiting NCT04742361 - Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer Phase 3
Completed NCT04400656 - PROState Pathway Embedded Comparative Trial
Completed NCT02282644 - Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry N/A
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT06305832 - Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer Phase 2
Recruiting NCT05761093 - Patient and Physician Benefit/ Risk Preferences for Treatment of mPC in Hong Kong: a Discrete Choice Experiment
Completed NCT04838626 - Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection Phase 2/Phase 3
Recruiting NCT03101176 - Multiparametric Ultrasound Imaging in Prostate Cancer N/A
Completed NCT03290417 - Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Prostate Cancer N/A
Completed NCT00341939 - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
Completed NCT01497925 - Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer Phase 1
Recruiting NCT03679819 - Single-center Trial for the Validation of High-resolution Transrectal Ultrasound (Exact Imaging Scanner ExactVu) for the Detection of Prostate Cancer
Completed NCT03554317 - COMbination of Bipolar Androgen Therapy and Nivolumab Phase 2
Completed NCT03271502 - Effect of Anesthesia on Optic Nerve Sheath Diameter in Patients Undergoing Robot-assisted Laparoscopic Prostatectomy N/A